Please login to the form below

Not currently logged in
Email:
Password:

neuroscience

This page shows the latest neuroscience news and features for those working in and with pharma, biotech and healthcare.

Shire offloads oncology unit to Servier for $2.4bn

Shire offloads oncology unit to Servier for $2.4bn

considering splitting up Shire and selling its neuroscience division to help finance the deal. ... The neuroscience arm includes Shire’s attention-deficit hyperactivity drugs such as Adderall XR (mixed amphetamine salts) and brought in $2.66bn in sales

Latest news

  • Novartis buys gene therapy firm AveXis for $8.7bn Novartis buys gene therapy firm AveXis for $8.7bn

    position in neuroscience and provide “another gene therapy platform, in addition to our CAR-T platform for cancer, to advance a growing pipeline of gene therapies across therapeutic areas”.

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Celgene has been adding to its pipeline on all fronts of late, with the latest deal also coming after a $2.1bn deal for three Prothena neuroscience drugs, signed last week,

  • Takeda mulls bid for Irish biopharma Shire Takeda mulls bid for Irish biopharma Shire

    In a press release announced earlier today, Takeda said a “potential transaction with Shire presents an opportunity to strengthen the company’s core therapeutic areas of oncology, gastrointestinal and neuroscience”.

  • Celgene bulks up pipeline again with $2.1bn Prothena deal Celgene bulks up pipeline again with $2.1bn Prothena deal

    Celgene’s acquisitive streak is continuing, with the US biotech handing over $150m upfront to secure option rights on three Prothena neuroscience programmes. ... Prothena has a legacy of innovation in neuroscience and a team with a deep understanding

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    Biogen has added another drug to its neuroscience pipeline, paying $75m upfront for rights to a Pfizer drug in development for cognitive impairment linked to schizophrenia. ... Pfizer was also developing the candidate for age-related hearing loss but has

More from news
Approximately 10 fully matching, plus 168 partially matching documents found.

Latest Intelligence

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    David Gray, senior neuroscientist at Pfizer’s Neuroscience Research Centre, adds: “One of the reasons we started BlueSky is that we wanted to show that what we are bringing forward is ... Since this article was written Pfizer has substantially scaled

  • Accelerating innovation Accelerating innovation

    Since he joined the French biopharmaceutical company he has seen it sharpen the focus of its research strategy, homing in even more on neuroscience, rare diseases and, especially, cancer.

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    Together with the Sheffield Institute of Translational Neuroscience at Sheffield University, a world authority on ALS, we are now testing some of these hypotheses in the lab.

  • Japanese pharma pulls no punches with post-Brexit UK Japanese pharma pulls no punches with post-Brexit UK

    It also recently launched neuroscience company Cerevance in Cambridge, Massachusetts in partnership with Lightstone Ventures, with the 25-person research team coming from Takeda’s Cambridge UK site.

  • Deal Watch August 2016 Deal Watch August 2016

    It has the same therapy areas as AstraZeneca apart from respiratory but also has neuroscience/pain, rare disease, vaccines and biosimilars.

More from intelligence
Approximately 2 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 40 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics